Machine learning in primary biliary cholangitis: A novel approach for risk stratification

Liver Int. 2022 Mar;42(3):615-627. doi: 10.1111/liv.15141. Epub 2022 Jan 7.

Abstract

Background & aims: Machine learning (ML) provides new approaches for prognostication through the identification of novel subgroups of patients. We explored whether ML could support disease sub-phenotyping and risk stratification in primary biliary cholangitis (PBC).

Methods: ML was applied to an international dataset of PBC patients. The dataset was split into a derivation cohort (training set) and a validation cohort (validation set), and key clinical features were analysed. The outcome was a composite of liver-related death or liver transplantation. ML and standard survival analysis were performed.

Results: The training set was composed of 11,819 subjects, while the validation set was composed of 1,069 subjects. ML identified four clusters of patients characterized by different phenotypes and long-term prognosis. Cluster 1 (n = 3566) included patients with excellent prognosis, whereas Cluster 2 (n = 3966) consisted of individuals at worse prognosis differing from Cluster 1 only for albumin levels around the limit of normal. Cluster 3 (n = 2379) included young patients with florid cholestasis and Cluster 4 (n = 1908) comprised advanced cases. Further sub-analyses on the dynamics of albumin within the normal range revealed that ursodeoxycholic acid-induced increase of albumin >1.2 x lower limit of normal (LLN) is associated with improved transplant-free survival.

Conclusions: Unsupervised ML identified four novel groups of PBC patients with different phenotypes and prognosis and highlighted subtle variations of albumin within the normal range. Therapy-induced increase of albumin >1.2 x LLN should be considered a treatment goal.

Keywords: artificial intelligence; autoimmune liver disease; cluster analysis; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cholagogues and Choleretics / therapeutic use
  • Cholangitis* / complications
  • Humans
  • Liver Cirrhosis, Biliary* / drug therapy
  • Machine Learning
  • Prognosis
  • Risk Assessment
  • Ursodeoxycholic Acid / therapeutic use

Substances

  • Cholagogues and Choleretics
  • Ursodeoxycholic Acid